Lobaplatin-Based Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Metastasis from Appendiceal and Colorectal Cancer: Safety and Efficacy Profiles
| Autor: | Qiang Feng, Jianwei Liang, Zheng Wang, Sicheng Zhou, Zheng Jiang, Haitao Zhou, Xishan Wang, Zhaoxu Zheng, Zheng Liu, Wei Pei, Haipeng Chen, Jing Zhang, Qian Liu, Jian-Jun Bi |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
safety medicine.medical_specialty Peritoneal metastasis Colorectal cancer morbidity Gastroenterology survival lobaplatin 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Overall survival Pathological Original Research HIPEC business.industry Cancer Perioperative medicine.disease Lobaplatin 030104 developmental biology Oncology Cancer Management and Research 030220 oncology & carcinogenesis peritoneal metastasis Hyperthermic intraperitoneal chemotherapy business |
| Zdroj: | Cancer Management and Research |
| ISSN: | 1179-1322 |
| Popis: | Wei Pei,1,* Sicheng Zhou,1,* Jing Zhang,2 Haitao Zhou,1 Haipeng Chen,1 Jianjun Bi,1 Zhaoxu Zheng,1 Zheng Liu,1 Zheng Jiang,1 Zheng Wang,1 Qian Liu,1 Xishan Wang,1 Jianwei Liang,1 Qiang Feng1 1Department of Colorectal Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, People’s Republic of China; 2Department of Abdominal Surgery, Huanxing Cancer Hospital, Beijing 100122, People’s Republic of China*These authors contributed equally to this workCorrespondence: Jianwei Liang; Qiang Feng Email Liangjw1976@163.com; 190977026@qq.comObjective: This study aimed to evaluate the safety and efficacy of lobaplatin in hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with peritoneal metastasis (PM) arising from colorectal or appendiceal cancer.Materials and Methods: Patients with synchronous or metachronous PM who underwent cytoreductive surgery (CRS) with HIPEC were systematically reviewed at the China National Cancer Center and Huanxing Cancer Hospital from June 2017 to June 2019. All enrolled patients were grouped into either lobaplatin or nonlobaplatin groups depending on the different chemotherapeutic agents used during HIPEC. Clinical characteristics, pathological features, perioperative parameters, and prognostic data were collected and analyzed.Results: A total of 100 patients were enrolled, with 48 patients in the lobaplatin group and 52 in the nonlobaplatin group. The two groups were well balanced in terms of clinicopathological characteristics. The two groups had comparable perioperative outcomes. However, more patients in the lobaplatin group than in the nonlobaplatin group developed abnormal platelet levels on postoperative day (POD)3 and abnormal ALT levels on POD5. Moreover, the average platelet count in the lobaplatin group was significantly lower than that in the nonlobaplatin group on POD5. There were no significant differences in the 3-year overall survival (OS) rates (48.4% vs 35.1%, P=0.298) and the 3-year progression-free survival (PFS) rates (34.9% vs 21.0%, P=0.470) of the two groups.Conclusion: Lobaplatin-based HIPEC is safe and feasible for the treatment of patients with PM arising from colorectal or appendiceal cancer with comparable low mortality and acceptable morbidity.Keywords: peritoneal metastasis, HIPEC, lobaplatin, morbidity, safety, survival |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|